World’s first CRISPR-based therapy to be offered on the NHS in England

Groundbreaking therapy, known as exagamglogene autotemcel (brand name Casgevy®), has been approved for use on the NHS in England, offering patients the prospect of a cure for severe sickle cell disease.

20 years and 1000 cases

We bring a rich history working with pioneers of their time on mission-critical, life-changing and industry-advancing innovations. For Panduit, a world-leading network infrastructure developer, we’re more than an extension of their in-house team. We’re family.

See why clients choose us

Client quote:

'I have often said that no one will out think, out prepare or out perform you. I am glad you are on our side!'

Our services have helped our clients’ innovations make a real difference; from the steel of the Golden Gate Bridge to cutting-edge cancer fighting pharmaceuticals.

Accolades

News & Updates

Requesting a Unitary Patent – What do I need to know?

Since the changes to the European patent system which led to the introduction of the Unitary Patent (UP) and the Unified Patent Court (UPC), we have been assisting more and more clients with obtaining UPs at the EPO.

Opposition Hotspots: Which medical technology sectors face the highest rate of EPO opposition?

Which MedTech sectors see the most oppositions at the EPO? Which MedTech patents are safer from being revoked or limited via EPO opposition?

Can “public prior use” be relied upon to invalidate European patents?

The “state of the art” for assessing novelty and inventive step at the European Patent Office includes “…everything made available to the public by means of a written or oral description, by use, or in any other way…”.

Upcoming events

29 May 2025 - Pharmaceutical patent strategy: building a portfolio to maximise value

An optimal pharmaceutical patent portfolio maximises the value of a drug, providing long term, robust patent protection to weather the storm of generic product launches, whilst also navigating a complex array of challenges such as clinical trial prior art and fast-followers.

Celebrating diversity: IP Inclusive

Fiercely committed to diversity, equity and inclusion, we were one of the first signatories of the IP Inclusive Charter, making a public commitment to supporting and promoting DEI in the IP professions. Additionally, we were founding members of IP Out, our LGBT+ chapter, and we regularly host events for Senior Women in IP and on neurodiversity, sustainability, and more.

Technology for Good

We care about the wider innovation and technology community, which is why we donate 1% of all annual profits to the Kilburn & Strode Innovation for All Foundation – thereby giving everyone the chance to both innovate and prosper. Our company’s existence is not isolated. It’s part of a wider system of people, values, other organisations and nature.

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us